Press Release: Uppsala,
Despite the fact that the demand for potency drugs is increasing, there are gaps among those on the market today that were introduced twenty years ago. Between 30 and 40 percent of patients do not respond well to treatment. Additionally, many men experience side effects such as headaches, abdominal pain, digestive problems and visual disturbances, leading many to choose to discontinue treatment. Another challenge is the short duration of the effect, maximum 36 hours.
Common to all existing drugs is that they are completely synthetic, called PDE-5 inhibitors, which facilitate the dilation of blood vessels in the penis. However, at the same time, PDE-5 inhibitors also affect blood vessels in other parts of the body, causing unwanted problems. The Dicot pharmaceutical company is developing a powerful new type of drug of organic origin and a semi-synthetic substance aimed at improving the performance of erectile dysfunction drugs.
– Meeting the challenges of today’s PDE-5 inhibitors is crucial in the development of our drug candidate LIB-01, which, among other things, has a duration of effect of more than seven days according to the results of animal studies. To confirm future clinical needs, we commissioned a series of interviews with leading sexual medicine physicians. They verify the need for better alternatives and point out that a drug with fewer side effects and a longer duration of effect is paramount. Doctor
For more information, please contact:
Goran Beijer CEO
Tel: +46 706 63 60 09
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a powerful agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with a significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at
Dicot is listed on
(c) Decision 2022. All rights reserved., sources